December 16, 2010 (Saint Genis Pouilly, France): Advanced Accelerator Applications (AAA), an emerging international leader in molecular nuclear medicine, today announced that it has received GMP (Good Manufacturing Practice) approval for the manufacture of Lutate, a radioactively labelled peptide that can be used to treat metastatic GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs).
The approval by the Italian Pharmaceutical Regulatory Authority (AIFA) will enable AAA to manufacture Lutate at its facility in Colleretto Giacosa, near Turin, Italy, making it the first industrial facility in the world approved to produce radio-labelled peptides for molecular nuclear therapy.
Neuroendocrine tumors are a rare group of tumors that start in the cells of the neuroendocrine system, a network of endocrine glands and cells throughout the body. Most GastroEnteroPancreatic tumors (GEPs) develop in the digestive system, usually starting in the stomach, bowel or pancreas.
Lutate,177Lutetium DOTA0-Tyr3-Octreotate, is a radiolabeled somatostatine analog which selectively targets somatostatine receptors which are over-expressed in tumor cells. The product was developed by AAA’s wholly-owned subsidiary, BioSynthema Inc, based in St Louis, Missouri, USA.
Lutate has been shown to be an effective and safe treatment for GEP-NETs in an investigator-sponsored clinical study at the Erasmus Medical Center, Rotterdam, Netherlands, where over 600 patients have been treated with this innovative radiopharmaceutical. The study showed Lutate extended patients’ lives by between 3.5 and six years in comparison to current treatments, including chemotherapy. It was also shown to significantly improve quality of life, as measured by a number of function and symptom scales, especially in patients with proven tumor regression.
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) have indicated the need for a Phase III study in order to prepare Lutate for registration. AAA has started a Parallel Scientific Advice (PSA) from the EMEA and FDA to discuss its Phase III protocol. The PSA system was introduced in 2006 to allow both agencies to exchange scientific views during the development phase of new drugs. AAA hopes to start a multicenter Phase III study in 2011 in both Europe and the United States, with potential approval anticipated in 2015.
Lutate has been granted Orphan Drug status by both the FDA and EMEA, which gives it protection from competition for seven years in the US and 10 years in Europe following approval.
Stefano Buono, Chief Executive Officer of AAA, commented “We hope that manufacturing Lutate for clinical study use and the absence of a valid therapeutic alternative will open up the possibility of treating patients in many countries during the registration phase. We anticipate that the Colleretto Giacosa site and a second potential facility for the production of Lutate and other Radio Metabolic Therapies at the IRST (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) in Meldola, Italy, would be able to produce sufficient quantities of Lutate to meet European demand, as well as developing new drugs.”
Dr. Jack Erion, CEO of BioSynthema, added, “Since merging with AAA we have reformulated Lutate to facilitate its use as a ready-to -use injectable drug. We have requested a Parallel Scientific Advice from EMA and FDA to discuss the Phase III protocol as this relatively new procedure seems particularly adapted to the development of Orphan Drugs”.
About Molecular Nuclear Medicine
Molecular Nuclear Medicine is a medical specialty using trace amounts of active substances, called radiopharmaceuticals, to create images of organs and lesions and to treat various diseases, like cancer. The technique works by injecting into the patient’s body targeted radiopharmaceuticals that accumulate in the organs or lesions that reveal specific biochemical processes.
Molecular Nuclear Diagnostics employs a variety of imaging devices and radiopharmaceuticals. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Tomography) are highly sensitive imaging technologies that enable physicians to diagnose different types of cancer, cardiovascular diseases, neurological disorders and other diseases in their early stages.
Molecular Nuclear Therapy uses radiopharmaceuticals that emit electrons, the same particles used in Radio Therapy (treating cancers using particle accelerators). By targeting special radiopharmaceuticals specifically to the tumors, these electrons are emitted only locally for a certain amount of time and cure by destroying the unhealthy tissues, allowing an efficient treatment and sparing surrounding healthy tissues. For the analogy to Radio Therapy, this technique is also called Radio Metabolic Therapy (RMT).
About Advanced Accelerator Applications
Advanced Accelerator Applications (www.adacap.com), is a European pharmaceutical company founded in 2002 to develop innovative diagnostic and therapeutic applications and products. AAA’s main research focus is in the field of Molecular Imaging and individualised therapy for patients with serious conditions (Personalized Medicine). AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. AAA currently has 10 production and R&D facilities in five countries (France, Italy, Switzerland, Spain and USA) and 133 employees.
For the year ending December 31, 2009, AAA reported revenues of €23.78 million, EBITDA of €5.84 million, total assets of €52.12 million and shareholders’ equity of €32.03 million.
About BioSynthema
Originally founded in 2001 in St. Louis (Missouri, USA) and now a subsidiary of AAA, BioSynthema Inc. (www.biosynthema.com) is molecular nuclear medicine discovery company specializing in the field of targeted molecular imaging and therapy. The company applies novel peptide technology to develop receptor-targeted compounds for radiotherapy that are used with a nearly identical diagnostic compound to pre-select patients for treatment. Its first priority is to advance the treatment of GEPNET patients with its lead therapy agent, Lutate. The company collaborates closely with researchers at the Erasmus Medical Centre in Rotterdam, The Netherlands, who have pioneered the field of peptide receptor radionuclide therapy, especially in regards to the treatment of GEP-NET patients.
Contacts
Advanced Accelerator Applications SA BioSynthema, Inc. Véronique Mermet Jack Erion 20 rue Diesel 4041 Forest Park Avenue 01630 Saint Genis Pouilly, France St. Louis, MO 63108 Tel: +33 4 50 99 30 70 Tel: +1-314-615- 63 65 www.adacap.com www.biosynthema.com info@adacap.com info@biosynthema.com
Media enquiries:
FD Financial Communications (UK) Stephanie Cuthbert Email: Stephanie.Cuthbert@fd.com T +44 (0)20 3077 0458 Jonathan Birt Email: Jonathan.Birt@fd.com T +44 (0)20 7269 7205
Twister Communications Group (Italy) Annalisa Bassi E-mail: abassi@twistergroup.it Tel: +39 02 438114218 Elisa Piacentino E-mail:epiacentino@twistergroup.it Tel: +39 02 438114602
